The 2022 OncoAlert Colloquium Day 6: EONS Sessions

The 2022 OncoAlert Colloquium Day 5: GI Oncology

NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy in locally advanced rectal cancer

HER-Vaxx is safe and provides clinical benefit over standard of care chemo for patients with HER2-overexpressing gastric cancer

Zolbetuximab + mFOLFOX6 as 1L treatment shows significantly prolonged PFS and OS in CLDN18.2+/ HER2 mG/GEJ adenocarcinoma

Kinetics of postop circulating cell-free DNA and impact on MRD detection rates in resected stage I-III colorectal cancer

OPERA: Nonoperative modality (NOM) treatments of rectal cancer do not compromise the chance of cure

NIVO + chemo and NIVO + IPI continue to demonstrate clinically meaningful survival benefit vs chemo for advanced ESCC

Epidemiology, detection, and management of NAFLD: a Latin American perspective

Optimisation of supportive, palliative and end of life care

What is required to advance data ethics, data sharing, and Open Science across LMICs

Access to Oncology Medicines Coalition - The Medicines Patent Pool